Values were close to what was demonstrated in a CRC study in Latin American patients, where 30% of patients (85 patients) had the KRAS test and 40.0% (34 patients) had KRAS mutant cancers [1]. The gene discussed is KRAS; the disease is colorectal carcinoma.